Alexandria, Va., USA – Jeremie Oliver, University of Utah, Salt Lake City, USA, presented the oral session “Intra-Amniotic Wnt Agonist Injection for Cleft Palate Correction” at the virtual 99th General Session & Exhibition of the International Association for Dental Research (IADR), held in conjunction with the 50th Annual Meeting of the American Association for Dental Research (AADR) and the 45th Annual Meeting of the Canadian Association for Dental Research (CADR), on July 21-24, 2021.
Oliver and colleagues aimed to establish an optimal therapeutic dosage, injection volume and treatment timing to promote survival of treated embryos and correction of cleft palate defects in-utero. Timed pregnant Pax9+/- mice mated with Pax9+/- males were identified at embryonic stages E11.5, E12.5, E13.5, E14.5 and E15.5 for intra-amniotic injection.
The results show that intra-amniotic delivery of small-molecule Wnt agonist therapy can be safely performed without compromising the embryo. There was a trend toward greater survival for embryos treated at later stages and with lower volumes. This study is the first toward establishing a model for intra-amniotic delivery of Wnt agonist for correction of Pax9 mutant mouse cleft palate defects and the first study to pilot a novel delivery protocol for Wnt agonist (IIIc3a) therapy by direct injection into the amniotic sac of mouse embryos.
View this oral session in the IADR General Session Virtual Experience Platform.
International Association for Dental Research
The International Association for Dental Research (IADR) is a nonprofit organization with over 10,000 individual members worldwide, with a mission to drive dental, oral and craniofacial research for health and well-being worldwide. To learn more, visit www.iadr.org.